yahoo_financeOriginal article
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Phase 2Halneuron®Positive
AI Analysis
Summary
Dogwood has enrolled the first 200 patients in its Phase 2b trial of Halneuron® for chemotherapy-induced peripheral neuropathy, with top-line data expected in Fall 2026.
Clinical Trial Data
Phase
2b
Patients
200
Importance:6/10
Sentiment:
0.30
Phase 2bClinical TrialPatient EnrollmentChemotherapy Induced Neuropathy
Related Companies
Read the original article
Published by yahoo_finance on July 20, 2026 12:30 PM